Opens in a new tab or window SAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body ...

The average 15.4%-22.9% weight losses across the tirzepatide doses achieved initially in the trial were maintained throughout ...

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

Novo Nordisk said on Friday its weight-loss drug met the main goals of a late-stage trial in patients with a type of fatty ...

Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide ...

This implies monthly maintenance doses, which would give it a big leg up on tirzepatide and semaglutide, which require weekly ...

Dumb Blonde” podcast host Bunnie Xo shared that she’s lost 4 lbs. on the weight-loss drug Tirzepatide and is now “pooping ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on ...

LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...

Scientists from Yale and other institutions have discovered that tirzepatide, a drug approved to treat type 2 diabetes, may also be highly effective for weight loss in people with obesity. This ...